Yitschak Biton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yitschak Biton has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Scott McNitt
Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY
22 shared publicationsWojciech Zareba
Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY
22 shared publicationsArthur J. Moss
Heart Research Follow‐up Program, Division of Cardiology, Department of Medicine University of Rochester Medical Center Rochester NY USA
21 shared publicationsIlan Goldenberg
Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY
18 shared publicationsBronislava Polonsky
Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY
15 shared publicationsValentina Kutyifa
Heart Research Follow-Up Program Division of Cardiology Department of Medicine University of Rochester Medical Center Rochester NY
14 shared publications
Latest Publications
- 17 October 2026
- Published by Elsevier in Journal of Electrocardiology
- Vol. 99, 154473
Unusual paroxysmal complete atrioventricular block after transcatheter aortic valve replacement
- 17 October 2026
- Published by Elsevier in Journal of Electrocardiology
- Vol. 99, 154473
Unusual paroxysmal complete atrioventricular block after transcatheter aortic valve replacement
- Open Access
- 28 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (2) , 170-187
Recent-onset atrial fibrillation: challenges and opportunities
Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
- 28 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (2) , 170-187
Open AccessRecent-onset atrial fibrillation: challenges and opportunities
Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
- 26 October 2021
- Published by Wolters Kluwer Health in Circulation
- Vol. 144 (17) , 1444-1448
Left Bundle-Branch Block Tachycardia After Transcatheter Aortic Valve Replacement
- 26 October 2021
- Published by Wolters Kluwer Health in Circulation
- Vol. 144 (17) , 1444-1448
Left Bundle-Branch Block Tachycardia After Transcatheter Aortic Valve Replacement
- 2 August 2019
- Published by Springer Nature in Current Cardiology Reports
- Vol. 21 (9) , 106
For Whom the Bell Tolls
Sudden cardiac death is one of the most important causes of death worldwide. Advancements in medical treatment, percutaneous interventions, and device therapy (ICD and CRTD) showed consistent reduction in mortality, mainly in survivors of SCD and in patients with ischemic cardiomyopathy and depressed left ventricular function. Patients with non-ischemic cardiomyopathies, mildly reduced LV function, and channelopathies have increased risk for SCD. Identifying the subgroup of these patients before they experience life-threatening or fatal events is essential to further improve outcomes. In this review, we aimed to summarize the current knowledge for risk stratification and primary prevention, to describe the gaps in evidence, and to discuss future directions for screening and treating patients at risk for SCD.Purpose of ReviewThe purpose of this review is to provide a comprehensive description of the etiologies of sudden cardiac death, risk stratification strategies, and to describe the current medical and interventional therapies. We aimed to discuss the current gaps in our knowledge of primary prevention of SCD and to review novel approaches and interventions.Recent FindingsThe incidence of SCD has decreased in the last two decades due to improved pharmacological treatment and ICD implantation in SCD survivors and in patients with reduced left ventricular function and ischemic cardiomyopathy. The efficacy of ICD in patients with non-ischemic cardiomyopathy is challenged by new findings from the DANISH trial. Catheter ablation is new emerging strategy to prevent SCD in patients with scar relater or PVC-triggered ventricular arrhythmias.SummaryDespite the new treatments, SCD is still a major burden. ICD remains the cornerstone for patients with ischemic cardiomyopathy, whereas appropriate risk stratification of the patients with non-ischemic cardiomyopathy and channelopathies is needed to further improve outcomes. The future of ablation as the treatment and prevention of SCD remains to be studied.
- 2 August 2019
- Published by Springer Nature in Current Cardiology Reports
- Vol. 21 (9) , 106
For Whom the Bell Tolls
Sudden cardiac death is one of the most important causes of death worldwide. Advancements in medical treatment, percutaneous interventions, and device therapy (ICD and CRTD) showed consistent reduction in mortality, mainly in survivors of SCD and in patients with ischemic cardiomyopathy and depressed left ventricular function. Patients with non-ischemic cardiomyopathies, mildly reduced LV function, and channelopathies have increased risk for SCD. Identifying the subgroup of these patients before they experience life-threatening or fatal events is essential to further improve outcomes. In this review, we aimed to summarize the current knowledge for risk stratification and primary prevention, to describe the gaps in evidence, and to discuss future directions for screening and treating patients at risk for SCD.Purpose of ReviewThe purpose of this review is to provide a comprehensive description of the etiologies of sudden cardiac death, risk stratification strategies, and to describe the current medical and interventional therapies. We aimed to discuss the current gaps in our knowledge of primary prevention of SCD and to review novel approaches and interventions.Recent FindingsThe incidence of SCD has decreased in the last two decades due to improved pharmacological treatment and ICD implantation in SCD survivors and in patients with reduced left ventricular function and ischemic cardiomyopathy. The efficacy of ICD in patients with non-ischemic cardiomyopathy is challenged by new findings from the DANISH trial. Catheter ablation is new emerging strategy to prevent SCD in patients with scar relater or PVC-triggered ventricular arrhythmias.SummaryDespite the new treatments, SCD is still a major burden. ICD remains the cornerstone for patients with ischemic cardiomyopathy, whereas appropriate risk stratification of the patients with non-ischemic cardiomyopathy and channelopathies is needed to further improve outcomes. The future of ablation as the treatment and prevention of SCD remains to be studied.
- Open Access
- 19 March 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (6) , e010346
Prognostic Importance of Defibrillator‐Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure
Background: Patients with heart failure and an implantable cardioverter‐defibrillator ( ICD ) for primary prevention are at increased mortality risk after receiving shock therapy. We sought to determine the prognostic significance of ICD therapies, both shock and antitachycardia pacing, delivered for different ventricular arrhythmia ( VA ) rates. Methods and Results: We evaluated mortality risk among 1790 ICD ‐implanted patients from MADIT ‐CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). For the first analysis, patients were divided into mutually exclusive groups by the rate of treated VA only: slow VA (P P =0.162). Consistently, shocks ( HR , 2.96; 95% CI , 1.91–4.60; P P =0.063) for fast VA were both associated with increased mortality risk. Shocks and antitachycardia pacing for slow VA were not significantly associated with increased mortality risk ( HR , 1.43 [95% CI , 0.52–3.92; P =0.489]; and HR , 1.43 [95% CI, 0.80–2.56; P =0.232], respectively). Conclusions: In patients with mild heart failure receiving ICD for primary prevention, mortality is associated with the rate of underlying VA rather than the type of therapy. These findings suggest that fast VA is a marker for increased mortality rather than shock therapy directly contributing to increased risk. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00180271.
- 19 March 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (6) , e010346
Open AccessPrognostic Importance of Defibrillator‐Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure
Background: Patients with heart failure and an implantable cardioverter‐defibrillator ( ICD ) for primary prevention are at increased mortality risk after receiving shock therapy. We sought to determine the prognostic significance of ICD therapies, both shock and antitachycardia pacing, delivered for different ventricular arrhythmia ( VA ) rates. Methods and Results: We evaluated mortality risk among 1790 ICD ‐implanted patients from MADIT ‐CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). For the first analysis, patients were divided into mutually exclusive groups by the rate of treated VA only: slow VA (P P =0.162). Consistently, shocks ( HR , 2.96; 95% CI , 1.91–4.60; P P =0.063) for fast VA were both associated with increased mortality risk. Shocks and antitachycardia pacing for slow VA were not significantly associated with increased mortality risk ( HR , 1.43 [95% CI , 0.52–3.92; P =0.489]; and HR , 1.43 [95% CI, 0.80–2.56; P =0.232], respectively). Conclusions: In patients with mild heart failure receiving ICD for primary prevention, mortality is associated with the rate of underlying VA rather than the type of therapy. These findings suggest that fast VA is a marker for increased mortality rather than shock therapy directly contributing to increased risk. Clinical Trial Registration: URL : http://www.clinicaltrials.gov . Unique identifier: NCT 00180271.
- Open Access
- 30 October 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (10) , 1358-1366
Predictors of long‐term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block
Background: Cardiac resynchronization therapy (CRT) is highly beneficial in patients with heart failure (HF) and left bundle branch block (LBBB); however, up to 30% of patients in this selected group are nonresponders.Hypothesis: We hypothesized that clinical and echocardiographic variables can be used to develop a simple mortality risk stratification score in CRT.Methods: Best‐subsets proportional‐hazards regression analysis was used to develop a simple clinical risk score for all‐cause mortality in 756 patients with LBBB allocated to the CRT with defibrillator (CRT‐D) group enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy. The score was used to assess the mortality risk within the CRT‐D group and the associations with mortality reduction with CRT‐D vs implantable cardioverter defibrillator (ICD) in each risk category.Results: Four clinical variables comprised the risk score: age ≥ 65, creatinine ≥ 1.4 mg/dL, history of coronary artery bypass graft, and left ventricular ejection fraction (LVEF) < 26%. Every 1 point increase in the score was associated with 2‐fold increased mortality within the CRT‐D arm (P < 0.001). CRT‐D was associated with mortality reduction as compared with ICD only in patients with moderate risk: score 0 (HR = 0.80, P = 0.615), score 1 (HR = 0.54, P = 0.019), score 2 (HR = 0.54, P = 0.016), score 3‐4 risk factors (HR = 1.08, P = 0.811); however, the device by score interaction was not significant (P = 0.306). The score was also significantly predictive of left ventricular reverse remodeling (P < 0.001).Conclusions: Four clinical variables can be used for improved mortality risk stratification in mild HF patients with LBBB implanted with CRT‐D.
- 30 October 2018
- Published by Wiley in Clinical Cardiology
- Vol. 41 (10) , 1358-1366
Open AccessPredictors of long‐term mortality with cardiac resynchronization therapy in mild heart failure patients with left bundle branch block
Background: Cardiac resynchronization therapy (CRT) is highly beneficial in patients with heart failure (HF) and left bundle branch block (LBBB); however, up to 30% of patients in this selected group are nonresponders.Hypothesis: We hypothesized that clinical and echocardiographic variables can be used to develop a simple mortality risk stratification score in CRT.Methods: Best‐subsets proportional‐hazards regression analysis was used to develop a simple clinical risk score for all‐cause mortality in 756 patients with LBBB allocated to the CRT with defibrillator (CRT‐D) group enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy. The score was used to assess the mortality risk within the CRT‐D group and the associations with mortality reduction with CRT‐D vs implantable cardioverter defibrillator (ICD) in each risk category.Results: Four clinical variables comprised the risk score: age ≥ 65, creatinine ≥ 1.4 mg/dL, history of coronary artery bypass graft, and left ventricular ejection fraction (LVEF) < 26%. Every 1 point increase in the score was associated with 2‐fold increased mortality within the CRT‐D arm (P < 0.001). CRT‐D was associated with mortality reduction as compared with ICD only in patients with moderate risk: score 0 (HR = 0.80, P = 0.615), score 1 (HR = 0.54, P = 0.019), score 2 (HR = 0.54, P = 0.016), score 3‐4 risk factors (HR = 1.08, P = 0.811); however, the device by score interaction was not significant (P = 0.306). The score was also significantly predictive of left ventricular reverse remodeling (P < 0.001).Conclusions: Four clinical variables can be used for improved mortality risk stratification in mild HF patients with LBBB implanted with CRT‐D.
- Open Access
- 26 June 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (2) , 339-346
Primary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients
Prospective data regarding the role of implantable cardioverter-defibrillator (ICD) for the primary prevention of sudden cardiac death in patients with long QT syndrome (LQTS) is scarce. Herein, we explore the prospective Rochester LQTS ICD registry to assess the risk for appropriate shock in primary prevention in a real-world setting. We studied 212 LQTS patients that had ICD implantation for primary prevention. Best-subsets proportional-hazards regression analysis was used to identify clinical variables that were associated with the first appropriate shock. Conditional models of Prentice, Williams, and Peterson were utilized for the analysis of recurrent appropriate shocks. During a median follow-up of 9.2 ± 4.9 years, there were 42 patients who experienced at least one appropriate shock and the cumulative probability of appropriate shock at 8 years was 22%. QTc ≥ 550 ms [hazard ratio (HR) 3.94, confidence interval (CI) 2.08–7.46; P < 0.001) and prior syncope on β-blockers (HR 1.92, CI 1.01–3.65; P = 0.047) were associated with increased risk of appropriate shock. History of syncope while on β-blocker treatment (HR 1.87, CI 1.28–2.72; P = 0.001), QTc 500–549 ms (HR 1.68, CI 1.10–2.81; P = 0.048), and QTc ≥ 550 ms (HR 3.66, CI 2.34–5.72; P < 0.001) were associated with increased risk for recurrent appropriate shocks, while β-blockers were not protective (HR 1.03, CI 0.63–1.68, P = 0.917). LQT2 (HR 2.10, CI 1.22–3.61; P = 0.008) and multiple mutations (HR 2.87, CI 1.49–5.53; P = 0.002) were associated with higher risk for recurrent shocks as compared with LQT1. In this prospective ICD registry, we identified clinical and genetic variables that were associated appropriate shock risk. These data can be used for risk stratification in high-risk patients evaluated for primary prevention with ICD.
- 26 June 2018
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 21 (2) , 339-346
Open AccessPrimary prevention with the implantable cardioverter-defibrillator in high-risk long-QT syndrome patients
Prospective data regarding the role of implantable cardioverter-defibrillator (ICD) for the primary prevention of sudden cardiac death in patients with long QT syndrome (LQTS) is scarce. Herein, we explore the prospective Rochester LQTS ICD registry to assess the risk for appropriate shock in primary prevention in a real-world setting. We studied 212 LQTS patients that had ICD implantation for primary prevention. Best-subsets proportional-hazards regression analysis was used to identify clinical variables that were associated with the first appropriate shock. Conditional models of Prentice, Williams, and Peterson were utilized for the analysis of recurrent appropriate shocks. During a median follow-up of 9.2 ± 4.9 years, there were 42 patients who experienced at least one appropriate shock and the cumulative probability of appropriate shock at 8 years was 22%. QTc ≥ 550 ms [hazard ratio (HR) 3.94, confidence interval (CI) 2.08–7.46; P < 0.001) and prior syncope on β-blockers (HR 1.92, CI 1.01–3.65; P = 0.047) were associated with increased risk of appropriate shock. History of syncope while on β-blocker treatment (HR 1.87, CI 1.28–2.72; P = 0.001), QTc 500–549 ms (HR 1.68, CI 1.10–2.81; P = 0.048), and QTc ≥ 550 ms (HR 3.66, CI 2.34–5.72; P < 0.001) were associated with increased risk for recurrent appropriate shocks, while β-blockers were not protective (HR 1.03, CI 0.63–1.68, P = 0.917). LQT2 (HR 2.10, CI 1.22–3.61; P = 0.008) and multiple mutations (HR 2.87, CI 1.49–5.53; P = 0.002) were associated with higher risk for recurrent shocks as compared with LQT1. In this prospective ICD registry, we identified clinical and genetic variables that were associated appropriate shock risk. These data can be used for risk stratification in high-risk patients evaluated for primary prevention with ICD.
- 30 May 2018
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 29 (7) , 1017-1023
Baseline adverse electrical remodeling and the risk for ventricular arrhythmia in Cardiac Resynchronization Therapy Recipients (MADIT CRT)
Introduction: Adverse electrical remodeling (AER), represented here as the sum absolute QRST integral (SAI QRST), has previously been shown to be directly associated with the risk for ventricular arrhythmia (VA). Cardiac resynchronization therapy (CRT) is known to reduce the risk for VA through various mechanisms, including reverse remodeling, and we aimed to evaluate the association between baseline AER and the risk for VA in CRT recipients.Methods and results: The study population comprised 961 CRT‐D implanted patients from the MADIT CRT study. The relationship between SAI QRST, VA risk, and VA risk/death was evaluated as a continuous and as a categorical variable–tertiles (T1 ≤ 0.527, T2 0.528–0.766, T3 > 0.766). In a multivariable model, AER was inversely associated with the risk of VA. Each unit increase in SAI QRST was associated with 64% (P = 0.007) and 54% (P = 0.003) decrease in the risk of VA and VA/death, respectively. Patients with high SAI QRST (T3) and medium SAI QRST (T2) had 52% (P < 0.001) and 32% (P = 0.027) reduced risk for VA and 44% (P = 0.002) and 26% (P = 0.055) reduced risk for VA/death as compared with patients with low SAI QRST (T1), respectively.Conclusion: In CRT implanted patients with mild heart failure, baseline AER was inversely associated with the risk for VA and VA/death; this is a finding that contradicts the relationship previously reported in non‐CRT implanted patients. We theorize that CRT may abate the process of AER; however, characterization of this mechanism requires further study.
- 30 May 2018
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 29 (7) , 1017-1023
Baseline adverse electrical remodeling and the risk for ventricular arrhythmia in Cardiac Resynchronization Therapy Recipients (MADIT CRT)
Introduction: Adverse electrical remodeling (AER), represented here as the sum absolute QRST integral (SAI QRST), has previously been shown to be directly associated with the risk for ventricular arrhythmia (VA). Cardiac resynchronization therapy (CRT) is known to reduce the risk for VA through various mechanisms, including reverse remodeling, and we aimed to evaluate the association between baseline AER and the risk for VA in CRT recipients.Methods and results: The study population comprised 961 CRT‐D implanted patients from the MADIT CRT study. The relationship between SAI QRST, VA risk, and VA risk/death was evaluated as a continuous and as a categorical variable–tertiles (T1 ≤ 0.527, T2 0.528–0.766, T3 > 0.766). In a multivariable model, AER was inversely associated with the risk of VA. Each unit increase in SAI QRST was associated with 64% (P = 0.007) and 54% (P = 0.003) decrease in the risk of VA and VA/death, respectively. Patients with high SAI QRST (T3) and medium SAI QRST (T2) had 52% (P < 0.001) and 32% (P = 0.027) reduced risk for VA and 44% (P = 0.002) and 26% (P = 0.055) reduced risk for VA/death as compared with patients with low SAI QRST (T1), respectively.Conclusion: In CRT implanted patients with mild heart failure, baseline AER was inversely associated with the risk for VA and VA/death; this is a finding that contradicts the relationship previously reported in non‐CRT implanted patients. We theorize that CRT may abate the process of AER; however, characterization of this mechanism requires further study.
- 1 March 2018
- Published by Elsevier in The American Journal of Cardiology
- Vol. 121 (5) , 615-620
Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure
- 1 March 2018
- Published by Elsevier in The American Journal of Cardiology
- Vol. 121 (5) , 615-620
Long-Term Survival With Implantable Cardioverter-Defibrillator in Different Symptomatic Functional Classes of Heart Failure
- 1 January 2018
- Published by Elsevier in Translational Research
- Vol. 191, 81-92.e7
Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications
- 1 January 2018
- Published by Elsevier in Translational Research
- Vol. 191, 81-92.e7
Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications